Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Sana Biotechnology, Inc.

35 indications, side-by-side phase, drug & LoA

$2.68

-0.07 (-2.5%)

D 34Pipeline Score Overvalued Biotech · Clinical
Market Cap
854.36 M
EPS
-0.94
P/E Ratio
-
Value Trade
8.11 M
SEC Financials
Q1 2026

  • Dilution Risk

    60%

  • R&D Expenses

    28.72 M

  • Operating CF

    -37.38 M

  • Total Assets

    373.59 M

  • Total Liabilities

    254.35 M

  • Equity

    119.24 M

  • D/E Ratio

    12,345

0.66 %
Week
-17.91 %
1 Month
-24.94 %
3 Month
-4.36 %
6 Month
-84.67 %
5 Year
-91.23 %
All Time
Cash Data
Caution

  • Cash Position

    101.14 M

  • Monthly Burn

    12.46 M

  • Runway

    7.1 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 11, 2026
Overview
Volume
2.25 M
52 Week Range
1.98 - 6.55
% held by Insiders
37.57 %
% held by Institutions
54.04 %
Enterprise Value
824.35 M
Total Shares
270.00 M
Short %
22.64 %
Float Shares
157.95 M
Company Description
HQ: 188 EAST BLAINE STREET, SUITE ...
Employees:142
https://www.sana.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
IND Submission example
SC451 Type 1 diabetes
IND
—
Cell Therapies
Endocrine System
SC451 Type 1 diabetes
IND
—
Cell Therapies
Endocrine System
SC451 Type 1 diabetes
IND
—
Cell Therapies
Endocrine System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D34
Pipeline Score
$343M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 40%
Micro Cap
(rank 544 of 905)
Percentile Rank
Sana Biotechnology, Inc. faces pipeline headwinds (34/100), with $1.6B risk-adjusted pipeline value, led by UP421 in Type1diabetes (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
UP421
Monoclonal antibody		Type1diabetesPhase 1NCT0623963651% $1.2B RECRUITING 2 - -Jun 1, 2025 -LOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
UP421
Type 1 Diabetes
Phase 1
2025-06-23
UP421
Type 1 Diabetes
Phase 1
2025-06-23
UP421
Type 1 Diabetes
Phase 1
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SANA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SANA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SANA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SANA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SANA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SANA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2027-01-150 0.00 0 0 - - - - - -
2027-01-150 0.00 0 0 - - - - - -
2027-01-150 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Sana Biotechnology, Inc. (SANA) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How SANA ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Vasculitis #10 of 16 PHASE 1 SC291
AZN GSK ABBV
$2.5B 0.69 FOLLOWER
Type 1 Diabetes #16 of 19 N/A UP421
LLY NVO SNY
$3.5B 0 FOLLOWER
Systemic Lupus Erythematosus #26 of 32 PHASE 1 SC291
BIIB VTRS BMY
$2.78B 0.69 FOLLOWER
Lymphoma #46 of 69 PHASE 1 SC262
REGN LLY MRK
$8.52B 0.71 FOLLOWER
Leukemia #53 of 64 PHASE 1 SC291
AMGN LLY AZN
$4.28B 0.66 FOLLOWER